Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of Pseudomonas aeruginosa in clinical isolates belonging to a Spanish nationwide multicenter study.

Enfermedades infecciosas y microbiología clínica
Xavier MuletGEMARA-SEIMC - REIPI Pseudomonas study group

Abstract

Pseudomonas aeruginosa causes severe infections, particularly in healthcare settings and immunocompromised patients in whom MDR and XDR isolates are more prevalent. The aim of this study is to validate a method based on MALDI-TOF spectra analysis for early detection of the ST175 high-risk clone (HRC). The MALDI-TOF spectra of the first 10 P. aeruginosa clinical isolates from each of the 51 participating Spanish hospitals were analyzed (n=506). Resistance profiles were determined by broth microdilution, and clonal epidemiology was assessed by PFGE analysis and multilocus sequence typing (MLST) in a previous study. Among all the isolates, 14.2% were XDR and 26.9% were non-susceptible to meropenem, while rates of resistance to ceftolozane/tazobactam (3.6%) and colistin (5.7%) were low. Up to 41.7% of all XDR isolates belonged to the ST175 clone, and most of them were only susceptible to ceftolozane/tazobactam and colistin. However, most of the resistance to ceftolozane/tazobactam among isolates belonging to this HRC was observed in carbapenemase-producing isolates. A model based on the presence of two MALDI-TOF biomarker peaks at m/z 6911 and 7359 yielded a negative predictive value (NPV) and a positive predictive value (PPV) of 9...Continue Reading

References

Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
Nov 8, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Carmen PeñaUNKNOWN Spanish Network for Research in Infectious Diseases (REIPI)
Aug 26, 2015·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Antonio OliverCarlos Juan
Jan 18, 2017·Trends in Microbiology·Marlène SaugetDidier Hocquet
Apr 5, 2017·The Journal of Infectious Diseases·Carlos JuanAntonio Oliver
Sep 7, 2017·Antimicrobial Agents and Chemotherapy·Ester Del Barrio-TofiñoAntonio Oliver
Jan 27, 2019·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Xavier MuletAntonio Oliver
Mar 4, 2019·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Céline SlekovecXavier Bertrand
Apr 17, 2019·The Journal of Antimicrobial Chemotherapy·Ester Del Barrio-TofiñoUNKNOWN GEMARA-SEIMC/REIPI Pseudomonas study Group
Aug 21, 2019·The Journal of Antimicrobial Chemotherapy·Ester Del Barrio-TofiñoUNKNOWN GEMARA-SEIMC/REIPI

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.